drugset / Trial / NCT02360514

Study to Evalutate Long-term Immunity of Hantavax in High Risk Population of HFRS

NCT02360514 ↗

Phase 3 Completed 226 enrolled Green Cross Corporation
RandomizedSingle-groupOpen-labelPrevention

Summary

This study was aimed evaluate long-term immunity response by neutralizing antibody test of adults in high risk population of HFRS .

Timeline

Start
2007-12
Primary completion
2012-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Hantavax Vaccine 0.5 ml Intramuscular

Indications